Amoy Diagnostics Co., Ltd. (300685.SZ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jiemin Luo | GM & Director | -- | -- | 1983 |
| Ms. Ying Chen | CFO, Accounting Supervisor & Secretary to the Board of Directors | -- | -- | 1970 |
| Mr. Ruan Li | Deputy GM, CTO & Director | -- | -- | 1978 |
| Mr. Frank Ron Zheng | Deputy GM & Director | -- | -- | 1990 |
| Mr. Huibin Zheng | Deputy General Manager | -- | -- | 1962 |
| Mr. Hongyu Wang | Deputy General Manager | -- | -- | 1984 |
Amoy Diagnostics Co., Ltd.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
Description
Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel, detects single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is based in Xiamen, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 30, 2024 at 12:00 AM UTC
Ex-Dividend Date